Alpha 2.0
Login Register
» Authors » M Ritgen

M Ritgen

Explore the profile of M Ritgen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 1690
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
M Kneba
S Bottcher
M Hallek
S Stilgenbauer
K Fischer
H Dohner
P Dreger
M Bruggemann
R Busch
A M Fink
Published In
Leukemia
Bone Marrow Transplant
Blood
Lancet
Clin Exp Immunol
Affiliations
Soon will be listed here.
Recent Articles
1.
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Al-Sawaf O, Robrecht S, Bahlo J, Fink A, Cramer P, V Tresckow J, et al.
Leukemia . 2020 Mar; 35(1):169-176. PMID: 32203141
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The...
2.
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
Furstenau M, Bahlo J, Fink A, Lange E, Dreger P, Dreyling M, et al.
Leukemia . 2019 Oct; 34(3):924-928. PMID: 31611627
No abstract available.
3.
Skin involvement by chronic lymphocytic leukaemia is frequently associated with unrelated neoplastic or inflammatory cutaneous disease and is not indicative of general disease progression
Thiesen I, Wehkamp U, Bruggemann M, Ritgen M, Murga Penas E, Klapper W, et al.
Br J Dermatol . 2018 Sep; 180(1):227-228. PMID: 30183072
No abstract available.
4.
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL
Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink A, Pflug N, et al.
Leukemia . 2016 May; 30(10):2019-2025. PMID: 27133817
This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter's transformations (RTs) following first-line treatment of chronic lymphocytic leukemia within four...
5.
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
Hahn M, Bottcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P, et al.
Bone Marrow Transplant . 2015 Jul; 50(10):1279-85. PMID: 26146810
To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL...
6.
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al.
Leukemia . 2013 Dec; 28(6):1299-307. PMID: 24342950
In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of...
7.
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
Fink A, Bottcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, et al.
Leukemia . 2013 Jun; 27(9):1949-52. PMID: 23787395
No abstract available.
8.
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
Rawstron A, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H, et al.
Leukemia . 2012 Oct; 27(1):142-9. PMID: 23041722
Detection of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) is becoming increasingly important as treatments improve. An internationally harmonised four-colour (CLR) flow cytometry MRD assay is widely used...
9.
Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease
Raff T, Kaiser M, Gokbuget N, Luschen S, Ritgen M, Trautmann H, et al.
Leukemia . 2012 Sep; 27(4):989-92. PMID: 23014567
No abstract available.
10.
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
Kalina T, Flores-Montero J, van der Velden V, Martin-Ayuso M, Bottcher S, Ritgen M, et al.
Leukemia . 2012 Sep; 26(9):1986-2010. PMID: 22948490
The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody...